Kras-Mutant
Entity.
- Evidence
- 64 documents · 38 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 1 Nov 2026
- Measured
- 0% of mentions say something specific about it; the rest only name it
- As of
- 5 Nov 2026
Where this comes from
- Cancer Med · 2026-10-30 · Divergent Roles of PIK3C3 in KRAS-Wild-Type and KRAS-Mutant Advanced Colorectal Cancer: Implications for 5-Fluorouracil Sensitivity and Prognosis. (opens the source in a new tab)
- Sci Adv · 2026-10-23 · CASTOR1 functional inactivation drives KRAS-mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression. (opens the source in a new tab)
- J Med Chem · 2026-10-22 · Discovery and Optimization of Isoform Selective ULK1 Degraders to Enhance Antitumor Activity in KRAS-Mutant Cancer. (opens the source in a new tab)
- Front Oncol · 2026-10-16 · Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis. (opens the source in a new tab)
- Phytomedicine · 2026-10-04 · Zuojin Wan reverses cetuximab resistance in KRAS-mutant colorectal cancer via the NRF2-GCH1/CoQ and DHODH/CoQ axes. (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-10-02 · Acute Metabolic Switch by High-Dose Dehydroascorbic Acid: Rapid TCA Cycle Depletion and Early Signature of Methionine Trap within 1 Hour in KRAS-Mutant Cells (opens the source in a new tab)
- Eur J Med Chem · 2026-09-27 · Design, synthesis, and structural optimization of novel pan-KRAS degrader for the treatment of KRAS-mutant pancreatic cancer (opens the source in a new tab)